Status:

UNKNOWN

Analgesic Efficacy of Dexmedetomidine as Adjuvant to Levobupivacaine in Ultrasound-guided Erector Spinae Plan Block for Modified Radical Mastectomy

Lead Sponsor:

South Egypt Cancer Institute

Conditions:

Acute Pain

Eligibility:

FEMALE

25-70 years

Phase:

PHASE2

PHASE3

Brief Summary

To evaluate the analgesic efficacy of dexmedetomidine as adjuvants to levobupivacaine in erector spinae plane block in modified radical mastectomy surgery.

Detailed Description

Premedication will be given, after complete fasting hours after applying standard monitors (noninvasive blood pressure, pulse oximetery, ECG, temperature and capnography), an intravenous cannula will ...

Eligibility Criteria

Inclusion

  • female patient
  • American society of anesthesiologists (ASA) I and II physical status
  • age from 25 to 70 years old
  • scheduled for either left or right modified radical mastectomy (MRM).

Exclusion

  • infection of the skin at or near site of needle puncture,
  • coagulopathy,
  • drug hypersensitivity or allergy to the studied drugs,
  • central or peripheral neuropathy,
  • significant organ dysfunction cardiac dysrrhythmias,
  • obesity (BMI\>35kg/m2)
  • recently use analgesic drugs.

Key Trial Info

Start Date :

November 1 2020

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 28 2021

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT04732377

Start Date

November 1 2020

End Date

December 28 2021

Last Update

February 1 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

South Egypt Cancer Institute

Asyut, Egypt, 171516